Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study to establish pharmacokinetics and safety of STI 2099 in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous injection of COVI-AMG™

X
Trial Profile

A clinical study to establish pharmacokinetics and safety of STI 2099 in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous injection of COVI-AMG™

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plutavimab (Primary) ; STI-2099 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 02 Mar 2021 According to a Sorrento Therapeutics media release, company has received clearance from the FDA for its Investigational New Drug application (IND) for this trial.
    • 11 Nov 2020 According to a Sorrento Therapeutics media release, the company has filed an investigational new drug application for intranasal (IN) COVI-DROPS (STI-2099).
    • 10 Nov 2020 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top